Vijaya Diagnostic Centre (VIJAYA) Q4 21/22 earnings summary

Executive summary

• FY22 marked the first full year following the September 2021 listing; revenue grew 23% and PAT crossed ₹1,100 mn.

• Operations served 3.62 mn patients across 95 centres and performed 9.32 mn tests; 15 centres opened during the year.

Financial highlights

• Consolidated revenue from operations rose 23% YoY to ₹46,236.99 lakh; EBITDA increased 23% to ₹20,369.01 lakh.

• Consolidated PAT was ₹11,066.76 lakh; basic EPS ₹10.76 and diluted EPS ₹10.69, versus ₹8.28 each in FY21.

• EBITDA margin was 44.1%; net profit margin was 23.9%. Non-Covid business grew 26% YoY.

• Operating cash flow was ₹15,799.87 lakh; capital expenditure on property, equipment and intangibles was ₹12,234.85 lakh.

Outlook and guidance

• Over the next two years, expansion targets include East India and adjacent geographies, alongside continued growth in existing markets and Tier 2/3 cities.

• Plans call for a Kolkata hub-and-spoke network, further South India expansion, and growth through company-owned centres and selective acquisitions.

• Growth priorities include non-Covid, radiology, wellness and preventive testing; a mobile app, web application and AI-enabled WhatsApp chatbot were nearing launch.